2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era Evaluation (ID: i777a) Survey

Question Title

* 2. What is your specialty?

MS Specialist

Neurologist

Other Specialist

Internal Medicine

Family Practice

Other (please specify)

Question Title

* 3. Please select the option that best describes your practice setting.

Academic medical center

Community medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 4. How many years have you been in practice?

1-10

11-20

>21

Question Title

* 5. How many patients with MS do you manage per week? 

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 6. After participating in this activity, how confident are you in the management of patients with MS in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Knowledge of current criteria for the diagnosis of MS

Knowledge of factors that predict poor prognosis in patients with MS

Knowledge of clinical trial evidence regarding the safety and efficacy of current and emerging DMTs for the treatment of MS

An understanding of the potential for reduction of disability accumulation and disease progression with early DMT

An understanding of how to tailor treatment plans based upon individual patient characteristics and preferences

An awareness of current recommendations for MS management during the COVID-19 era

Question Title

* 8. How committed are you to making changes in your practice based on your participation in this activity? 

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 9. What barriers do you see to making changes in your practice? Please select all that apply.

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Recognize the importance of early diagnosis and treatment in reducing disability progression among patients with MS	Recognize the importance of early diagnosis and treatment in reducing disability progression among patients with MS Strongly agree	Recognize the importance of early diagnosis and treatment in reducing disability progression among patients with MS Agree	Recognize the importance of early diagnosis and treatment in reducing disability progression among patients with MS Neutral	Recognize the importance of early diagnosis and treatment in reducing disability progression among patients with MS Disagree	Recognize the importance of early diagnosis and treatment in reducing disability progression among patients with MS Strongly disagree
Personalize treatment selection when starting, switching, or stopping a pharmacologic treatment based on efficacy, safety, and patient preference	Personalize treatment selection when starting, switching, or stopping a pharmacologic treatment based on efficacy, safety, and patient preference Strongly agree	Personalize treatment selection when starting, switching, or stopping a pharmacologic treatment based on efficacy, safety, and patient preference Agree	Personalize treatment selection when starting, switching, or stopping a pharmacologic treatment based on efficacy, safety, and patient preference Neutral	Personalize treatment selection when starting, switching, or stopping a pharmacologic treatment based on efficacy, safety, and patient preference Disagree	Personalize treatment selection when starting, switching, or stopping a pharmacologic treatment based on efficacy, safety, and patient preference Strongly disagree
Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS	Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Strongly agree	Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Agree	Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Neutral	Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Disagree	Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Strongly disagree
Evaluate potential benefits of emerging therapies in delaying disability, slowing disease progression, and improving long-term outcomes in MS	Evaluate potential benefits of emerging therapies in delaying disability, slowing disease progression, and improving long-term outcomes in MS Strongly agree	Evaluate potential benefits of emerging therapies in delaying disability, slowing disease progression, and improving long-term outcomes in MS Agree	Evaluate potential benefits of emerging therapies in delaying disability, slowing disease progression, and improving long-term outcomes in MS Neutral	Evaluate potential benefits of emerging therapies in delaying disability, slowing disease progression, and improving long-term outcomes in MS Disagree	Evaluate potential benefits of emerging therapies in delaying disability, slowing disease progression, and improving long-term outcomes in MS Strongly disagree
Identify up-to-date recommendations for patients with MS during COVID-19 era, including registries and treatment considerations	Identify up-to-date recommendations for patients with MS during COVID-19 era, including registries and treatment considerations Strongly agree	Identify up-to-date recommendations for patients with MS during COVID-19 era, including registries and treatment considerations Agree	Identify up-to-date recommendations for patients with MS during COVID-19 era, including registries and treatment considerations Neutral	Identify up-to-date recommendations for patients with MS during COVID-19 era, including registries and treatment considerations Disagree	Identify up-to-date recommendations for patients with MS during COVID-19 era, including registries and treatment considerations Strongly disagree

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Faculty for this activity was effective	Faculty for this activity was effective Strongly agree	Faculty for this activity was effective Agree	Faculty for this activity was effective Neutral	Faculty for this activity was effective Disagree	Faculty for this activity was effective Strongly disagree
Content was scientifically rigorous and evidence based	Content was scientifically rigorous and evidence based Strongly agree	Content was scientifically rigorous and evidence based Agree	Content was scientifically rigorous and evidence based Neutral	Content was scientifically rigorous and evidence based Disagree	Content was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 12. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 1. What is your degree?

Question Title

* 2. What is your specialty?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. How many years have you been in practice?

Question Title

* 5. How many patients with MS do you manage per week?

Question Title

* 6. After participating in this activity, how confident are you in the management of patients with MS in your practice?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 9. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree After participating in today’s activity, I am now able to:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Question Title

* 12. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

* 5. How many patients with MS do you manage per week? 

* 8. How committed are you to making changes in your practice based on your participation in this activity? 

* 10. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now able to:

* 11. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree